- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03414190
Impact of Text Messages to Promote Secondary Prevention After Acute Coronary Syndrome (IMPACS)
Impact of a Mobile Phone Text Messages Intervention on the Secondary Prevention of Cardiovascular Events After Acute Coronary Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Purpose of the trial: The purpose of the study is to evaluate the effectiveness of automated mobile phone text message-based intervention for secondary prevention after acute coronary syndrome hospitalization.
Trial design: Two-parallel arm, single-blind, block randomization.
Primary endpoint: The proportion achieving guideline levels of modifiable risk factors (LDL-C <70mg/dL, blood pressure <140/90 mm Hg, exercising regularly [≥5 d/wk × 30minutes of moderate exercise per session], nonsmoker status, and BMI <25). The investigators prespecified in the statistical analysis plan the efficacy variable of proportion achieving combined risk factor control (achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed above) as a measure of a multiple risk factor effect.
Secondary endpoints: The plasma LDL-C level at 6 months, Level of physical activity, Blood Pressure, Medication adherence measured via Morisky scale, Proportion of non-smokers, Body mass index (BMI), Rates death and hospitalization up to 6 months.
Duration of follow-up: 6 months
Trial treatment:
Intervention: The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts. There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients. Texts will be sent out 4 times per week for 180 days. All participants in the same stream will receive the same texts in the same order.
Control: The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome. The participants will also receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
Expected sample size, enrollment and expected number of centers:
Sample size = 160 Recruitment start date: November, 2017 Recruitment end date: May, 2019 Follow-up end date: November, 2019 Number of centers: 1
Statistical considerations:
- Intention to treat analysis
- The trial has >90% power (2 sided alpha = 0.05) to detect 15% difference in achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
MG
-
Belo Horizonte, MG, Brazil, 30575210
- Recruiting
- Luiz Guilherme Passaglia
-
Contact:
- Luiz G Passaglia, master's
- Phone Number: 3199038674
- Email: lg.passaglia@uol.com.br
-
Principal Investigator:
- Luiz G Passaglia, M.D.
-
Principal Investigator:
- Antônio LP Ribeiro, M.D., Ph.D
-
Sub-Investigator:
- Luisa CC Brant, M.D., Ph.D
-
Sub-Investigator:
- Bruno R Nascimento, M.D., Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Consecutive patients who have been hospitalized at the UFMG's University Hospital with primary or secondary diagnosis of Acute Coronary Syndrome and are discharged for outpatient follow-up;
- Age ≥ 18 years, of both sexes;
- Patients who are able to receive text messages by their own mobile phone.
Exclusion Criteria:
- Refusal or inability to sign the Informed Consent.
- Complete illiteracy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Automated semi-personalized mobile phone text message-based intervention for secondary prevention plus usual care.
|
The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention.
The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts.
There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients.
Texts will be sent out 4 times per week for 180 days.
All participants in the same stream will receive the same texts in the same order.
The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome.
They will also receive simple and short text messages related to the importance of trial participation.
|
No Intervention: No Intervention
Usual Care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Escore of combined risk factor control
Time Frame: 6 months
|
The proportion achieving guideline levels of modifiable risk factors (LDL-C <77mg/dL, blood pressure <140/90 mm Hg, exercising regularly [≥5 d/wk × 30minutes of moderate exercise per session], nonsmoker status, and BMI <25).
We prespecified in the statistical analysis plan the efficacy variable of proportion achieving combined risk factor control (achieving risk factor targets in 4 or more of the 5 modifiable risk factors listed above) as a measure of a multiple risk factor effect
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma LDL-C level
Time Frame: 6 months
|
Fasting blood sample
|
6 months
|
Level of physical activity (measured via
Time Frame: 6 months
|
Measured by research blinded to treatment allocation - The level of physical activity will be mensured by the International Physical Activity Questionnaire Short Form (IPAQ-SF) and it will be validated in one-fifth of the participants by using accelerometers
|
6 months
|
Blood Pressure
Time Frame: 6 months
|
Measured by research blinded to treatment allocation - 3 resting, sitting digital recordings, mean of last 2 readings
|
6 months
|
Proportion of non-smokers
Time Frame: 6 months
|
Measured by research blinded to treatment allocation - Self-reported smoking / quitting attempts will be confirmed with a Carbon Monoxide Meter Breath Test
|
6 months
|
Body mass index (BMI)
Time Frame: 6 months
|
Measured by research blinded to treatment allocation
|
6 months
|
Medication adherence (measured via "Medida de adesão aos tratamentos" - MAT)
Time Frame: 6 months
|
Measured by research blinded to treatment allocation It is an instrument composed of seven items that evaluate the behavior of the individual in relation to daily use of medicines.
The answers are obtained by means of a six-point ordinal scale that varies from always (1) to never (6).
The values obtained with the answers to the seven items are summed and divided by the number of items (values vary from 1 to 6).
Subsequently, values 5 and 6 are computed as one (adherent) and the others are computed as zero (non-adherent).
|
6 months
|
Death from any cause
Time Frame: 6 months
|
Medical records and database
|
6 months
|
Rehospitalization
Time Frame: 6 months
|
Self-report, medical records and database
|
6 months
|
Cardiovascular death
Time Frame: 6 months
|
Medical records and database
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CEP1.883.227
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
Clinical Trials on Mobile phone text message
-
The University of Hong KongHospital Authority, Hong KongUnknownDiabetes Mellitus, Type 2 | Appointments and SchedulesHong Kong
-
Yaounde Central HospitalCIHR Canadian HIV Trials NetworkCompleted
-
Assistance Publique - Hôpitaux de ParisCompletedType 1 DiabetesFrance
-
NYU Langone HealthCompleted
-
Federal University of Juiz de ForaUniversity of Kansas Medical CenterCompletedTobacco Use Disorder | Tobacco Use CessationBrazil
-
KEMRI-Wellcome Trust Collaborative Research ProgramUniversity of Oxford; African Population and Health Research CenterEnrolling by invitationEpilepsy | Treatment AdherenceKenya
-
Northwestern UniversityCompleted
-
Alexandria UniversityHigh Institute of Public Health, EgyptCompleted
-
San Francisco Veterans Affairs Medical CenterVA Palo Alto Health Care System; North Texas Veterans Healthcare System; North... and other collaboratorsRecruiting
-
University of California, DavisUniversity of California, San Francisco; Public Hospital Roatan, HondurasCompletedBreastfeeding | Breastfeeding, ExclusiveHonduras